The efficacy data are very encouraging for a highly pre-treated patient group with advanced melanoma. The MITCI response rate is comparable to the 56% (10/18) response rate reported by Puzanov et al at ASCO 2015 for Yervoy combined with Amgen’s approved oncolytic virotherapy, Imlygic (T-Vec). We note that the Puzanov study was in patients who had not undergone any systemic therapy and included patients with less severe Stage IIIB disease.
Cavatack Mitci
50 Percent response rate Including in Heavily Pretreated Patients.
